In December 2020, DZD9008 was added to the NMPA’s list of “breakthrough” drugs for treating locally advanced or metastatic NSCLC harboring an EGFR ex20ins in patients who have previously received chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.